ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

ClinicalTrials.gov ID: NCT03897075

Public ClinicalTrials.gov record NCT03897075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Study identification

NCT ID
NCT03897075
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Enrollment
99 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Tildrakizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 12, 2021
Primary completion
Apr 4, 2024
Completion
Jan 29, 2025
Last update posted
Mar 31, 2026

2021 – 2025

United States locations

U.S. sites
11
U.S. states
5
U.S. cities
11
Facility City State ZIP Site status
California Dermatology & CRI (Site 18) Encinitas California 92007
First OC Dermatology (Site 07) Fountain Valley California 92708
Dermatology Research Associates (Site 09) Los Angeles California 90045
Clinical Science Institute (Site 14) Santa Monica California 90404
Florida Academic Centers Research and Education, LLC (Site 21) Coral Gables Florida 33134
Renstar Medical Research (Site 23) Ocala Florida 34470
Forest Hills Dermatology Group (Site 04) Forest Hills New York 11375
Clinical Partners, LLC (Site 08) Johnston Rhode Island 02919
Center for Clinical Studies Cypress (Site 17) Cypress Texas 77433
Center for Clinical Studies (Site 11) Houston Texas 77004
Progressive Clinical Research (Site 27) San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03897075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03897075 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →